Export 255 results:
[ Author
Filters: First Letter Of Last Name is C [Clear All Filters]
“Structure, function and diversity of the healthy human microbiome.”, Nature, vol. 486, no. 7402, pp. 207-14, 2012.
“Structure, Function and Diversity of the Healthy Human Microbiome”, Nature, vol. 486, pp. 207-214, 2012.
, “A framework for human microbiome research.”, Nature, vol. 486, no. 7402, pp. 215-21, 2012.
“A Framework for Human Microbiome Research”, Nature, vol. 486, pp. 215-221, 2012.
, “Clinical trials referral resource. Targeted therapy in squamous cell cancers of the head and neck.”, Oncology (Williston Park), vol. 16, no. 5, pp. 621-2, 625-6, 2002.
, “Clinical trials, referral resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck.”, Oncology (Williston Park), vol. 14, no. 4, pp. 553-4, 559, 561, 2000.
, “Clinical trials resource. Treatment of advanced or recurrent squamous cell carcinoma of the head and neck”, Oncology, vol. 14, pp. 553-554559
561, 2000.
, “Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation.”, J Am Soc Nephrol, vol. 8, no. 12, pp. 1930-41, 1997.
, “EVITA Dengue: a Cluster-Randomized Controlled Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral Infection in Brazil”, Trials, vol. 23, no. 1, p. 185, 2022.
, “Stroke Version 2.0 Common Data Element (CDE) Review: Updates to the National Institute of Neurological Disorders and Stroke (NINDS) CDEs for Stroke”, in American Academy of Neurology 71st Annual Meeting, Philadelphia, PA, 2019.
, , “Clinical trials referral resource. Current clinical trials of epothilone B analog (BMS-247550).”, Oncology (Williston Park), vol. 15, no. 9, pp. 1168-9, 1172-5, 2001.
, “Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.”, Oncology (Williston Park), vol. 18, no. 14, pp. 1778, 1781-2, 1784, 2004.
, “Accuracy of Three Screening Tools for Prenatal Substance Use.”, Obstet Gynecol, vol. 133, no. 5, pp. 952-961, 2019.
, , “Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.”, Clin Infect Dis, vol. 55, no. 11, pp. 1495-502, 2012.
, “Determining Population and Developmental Pharmacokinetics of Metronidazole using Plasma and Dried Blood Spot Samples from Premature Infants”, Pediatr Infect Dis J, vol. 32, no. 9, pp. 956-61, 2013.
, “Determining Population and Developmental Pharmacokinetics of Metronidazole Using Plasma and Dried Blood Spot Samples from Premature Infants”, Pediatr Infect Dis J, vol. 32, pp. 956-961, 2013.
, “Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.”, N Engl J Med, vol. 382, no. 20, pp. 1906-1915, 2020.
, , “Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years.”, Epilepsy Behav, vol. 29, no. 2, pp. 308-15, 2013.
, “Antigen-specific T-lymphocyte function after cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 12, no. 12, pp. 1335-42, 2006.
, “Antigen-Specific T-Lymphocyte Function After Cord Blood Transplantation”, Biol Blood Marrow Transplant, vol. 12, pp. 1335-1342, 2006.
, “Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years.”, Epilepsy Behav, vol. 22, no. 2, pp. 240-6, 2011.
, “Fetal Antiepileptic Drug Exposure: Adaptive and Emotional/Behavioral Functioning at Age 6 Years”, Epilepsy Behav, vol. 29, pp. 308-315, 2013.
,